Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the PhaseIII BREAKWATER trial.
source https://www.sciencedaily.com/releases/2025/01/250125152749.htm
Researchers discover how to turn one germ's drug resistance into an
Achilles' heel
-
Decades of reliance on the antibiotic rifampicin have fueled the rise of
drug-resistant Mycobacterium tuberculosis (Mtb). But as the bacterium
mutates to p...
10 hours ago
Welcome to the 'The Fact Factory' friends. Its an interesting Hot Spot which brings to you amazing and little known facts from all over the world. So, sit back, take a tour around the world and enjoy the trivia.
No comments:
Post a Comment